Views & Analysis | Perspectives on pharma industry issues

Sales & Marketing

Four reasons pharma is sweeping the Super Bowl despite FDA f...

The FDA has signalled increased scrutiny of D2C pharma advertising. So why is pharma stepping up its advertising at Super Bowl LX?

R&D

The long-delayed promise of the microbiome, with Sam Possemi...

Sam Possemiers, CEO of MRM Health, believes that the microbiome space is finally coming into maturity.

Digital

From engagement metrics to meaningful experience: Why pharma...

Pharma digital success still focuses on clicks and downloads, but true performance is whether content actually meets real end-user needs

R&D

startup discussion investment ideas visual

Strategies for creating an ecosystem to support early-stage ...

Learn how to foster growth for early-stage biotech companies through innovative ecosystem strategies and valuable CDMO collaborations

Market Access

Biotech leaders: ‘They're shoving this industry into the arm...

At the Biotech Showcase during JPM Week, biotech leaders expressed frustration at the US's lack of concern about Chinese biotech progress.

R&D

Alzheimer’s drugs: An overview and update

When we covered JP Morgan in January, over and over we heard that neurodegenerative diseases, especially Alzheimer’s, were going to be one of the most exciting spaces in pharma this year.

R&D

Manufacturing gene therapies, oncolytic viruses, and vaccine...

The Alliance for Regenerative Medicine’s (ARM) Cell & Gene Meeting on the Med, took place in Barcelona back in April.

Market Access

SteinCares and Sandoz: Bringing high-quality healthcare prod...

Recently, pharmaphorum spoke with Sebastian Katz, chief strategy officer of specialty healthcare company Stein Holding Group (SteinCares), to discuss the announcement of its licensing agree

Sales & Marketing

Four reasons pharma is sweeping the Super Bowl despite FDA f...

The FDA has signalled increased scrutiny of D2C pharma advertising. So why is pharma stepping up its advertising at Super Bowl LX?

Sales & Marketing

pharmaphorum podcast Episode 243, Lisa Sims, Novartis

On quality data for quality learnings, with Lisa Sims

Nicole Raleigh speaks with Lisa Sims, executive director of learning strategy & operations at Novartis, about personalising learning at scale.

Digital

From engagement metrics to meaningful experience: Why pharma...

Pharma digital success still focuses on clicks and downloads, but true performance is whether content actually meets real end-user needs

Digital

Activation of the G protein-coupled GABA B receptor by the agonist baclofen

How GenAI is cracking the toughest targets in drug discovery

Generative AI has the potential to solve for designing effective antibodies for G‑protein coupled receptors (GPCRs).

Market Access

Biotech leaders: ‘They're shoving this industry into the arm...

At the Biotech Showcase during JPM Week, biotech leaders expressed frustration at the US's lack of concern about Chinese biotech progress.

Market Access

European biopharma at a crossroads

If Europe can bridge its operational gaps while leveraging its scientific base, it can carve out a distinctive and sustainable leadership position.

Oncology

A cancer treatment modality that prioritises QoL, with Ben Z...

Immuneering's Ben Zeskind explains how, by focusing on quality of life as well as quantity, they've created a drug for pancreatic cancer.

Oncology

Improving breast cancer outcomes in sub-Saharan Africa

New funding from The Pfizer Foundation will support breast cancer efforts in Kenya by the Academic Model Providing Access to Healthcare (AMPATH).

Oncology

Engineering “smarter” cells, with Tim Lu

Senti Bio's Tim Lu discusses “logic-gated” cells, which have multiple receptors allowing them to attack cancer cells while leaving healthy cells alone